Title : Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.

Pub. Date : 2011 Jun

PMID : 21427706






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We hypothesized that JX-594 and sorafenib, a small molecule inhibitor of B-raf and vascular endothelial growth factor receptor (VEGFR) approved for HCC, would have clinical benefit in combination given their demonstrated efficacy in HCC patients and their complementary mechanisms-of-action. Sorafenib B-Raf proto-oncogene, serine/threonine kinase Homo sapiens